Dyne Therapeutics, Inc. Increase (Decrease) in Other Noncurrent Assets
Dyne Therapeutics, Inc. (DYN) reported Increase (Decrease) in Other Noncurrent Assets of -$4.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-07-29
- Dyne Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was -$4.35M.
- Dyne Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was -$28.00K.
- Dyne Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was -$350.00K.
- Dyne Therapeutics, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $12.99M.
- Dyne Therapeutics, Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was $12.64M.
- Dyne Therapeutics, Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was $0.00.
- Dyne Therapeutics, Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$4.38M 10-Q · filed 2026-07-29 | -$4.73M derived: sum of 3 quarters · filed 2026-07-29 | $8.26M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$28.00K 10-Q · filed 2026-05-11 | -$378.00K derived: sum of 2 quarters · filed 2026-05-11 | $12.61M derived: sum of 3 quarters · filed 2026-05-11 | $12.61M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $12.64M derived: sum of 2 quarters · filed 2026-03-02 | $12.64M derived: sum of 3 quarters · filed 2026-07-29 | $12.64M 10-K · filed 2026-03-02 |
| 2025-09-30 | $12.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $12.99M derived: sum of 2 quarters · filed 2026-07-29 | $12.99M 10-Q · filed 2025-11-05 | $12.99M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $0.00 10-Q · filed 2026-07-29 | $0.00 derived: sum of 3 quarters · filed 2026-07-29 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2021-06-30 | $578.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |